Documenti fondamentali

Visualizza tutta la documentazione

Vai a

R0908

R1881

Name: R1881
Brand: SIGMA

≥98% (HPLC), Androgen receptor agonist, powder

Sinonimo/i:

(17b)-17-Hydroxy-17-methyl-Estra-4,9,11-trien-3-one, Methyltrienolone, Metribolone, NSC 92858, RU 1881

Autenticati per visualizzare i prezzi organizzativi e contrattuali.

Scegli un formato

Cambia visualizzazione

Taglio della confezione	SKU	Disponibilità	Prezzo

Informazioni su questo articolo

Formula empirica (notazione di Hill):

C₁₉H₂₄O₂

Numero CAS:

965-93-5

Peso molecolare:

284.39

UNSPSC Code:

51111800

PubChem Substance ID:

329823993

NACRES:

NA.77

MDL number:

MFCD00199021

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

Prezzi e disponibilità al momento non sono disponibili

Servizio Tecnico

Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.

Permettici di aiutarti

Proprietà

Nome del prodotto

R1881, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -48 to -68°

drug control

USDEA Schedule IIIN; Home Office Schedule 4.2; regulated under CDSA - not available from Sigma-Aldrich Canada

color

light yellow to yellow

solubility

DMSO: ≥10 mg/mL

storage temp.

2-8°C

SMILES string

C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3C=C[C@]12C

InChI

1S/C19H24O2/c1-18-9-7-15-14-6-4-13(20)11-12(14)3-5-16(15)17(18)8-10-19(18,2)21/h7,9,11,16-17,21H,3-6,8,10H2,1-2H3/t16-,17+,18+,19+/m1/s1

InChI key

CCCIJQPRIXGQOE-XWSJACJDSA-N

Descrizione

Biochem/physiol Actions

Androgen receptors (ARs) are nuclear hormone receptors/transcription factors. R1881, also known as methyltrienolone, is a synthetic androgen. It is the gold standard AR agonist.

R1881 (methyltrienolone) is a potent synthetic androgen.

Features and Benefits

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 1

Questo articolo	SML2321	N129	E3375
Sigma-Aldrich R0908 R1881	Sigma-Aldrich SML2321 Gestrinone	Sigma-Aldrich N129 Naloxone methiodide	Sigma-Aldrich E3375 trans-Androsterone
form powder	form powder	form solid	form powder
assay ≥98% (HPLC)	assay ≥97% (HPLC)	assay ≥98% (HPLC)	assay ≥98% (HPLC)
drug control USDEA Schedule IIIN; Home Office Schedule 4.2; regulated under CDSA - not available from Sigma-Aldrich Canada	drug control -	drug control -	drug control -
Quality Level 100	Quality Level -	Quality Level 100	Quality Level 200
storage temp. 2-8°C	storage temp. 2-8°C	storage temp. 2-8°C	storage temp. room temp
solubility DMSO: ≥10 mg/mL	solubility DMSO: 2 mg/mL, clear	solubility H₂O: >10 mg/mL	solubility chloroform: 50 mg/mL, clear to slightly hazy, colorless to faintly yellow

Classe di stoccaggio

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

Nader Al Nakouzi et al.

European urology, 68(2), 228-235 (2014-05-20)

Cabazitaxel, abiraterone acetate (AA), and enzalutamide have been approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel chemotherapy. Whether taxanes and next-generation androgen receptor (AR) axis inhibitors are cross-resistant or not is a subject of

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

Juliet Richards et al.

Cancer research, 72(9), 2176-2182 (2012-03-14)

Prostate cancer progression can be associated with androgen receptor (AR) mutations acquired following treatment with castration and/or an antiandrogen. Abiraterone, a rationally designed inhibitor of CYP17A1 recently approved for the treatment of docetaxel-treated castration-resistant prostate cancer (CRPC), is often effective

Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer.

Lingyan Jin et al.

Cancer research, 77(20), 5564-5575 (2017-08-19)

Resistance invariably develops to antiandrogen therapies used to treat newly diagnosed prostate cancers, but effective treatments for castration-resistant disease remain elusive. Here, we report that the transcriptional coactivator CBP/p300 is required to maintain the growth of castration-resistant prostate cancer. To

Visualizza tutti i documenti correlati

Numero articolo commerciale globale

SKU	GTIN
R0908-10MG	04061836694098
R0908-50MG	04061832867755

Questions

Anonymous

7 months ago

Hello, I’d like to treat my organoids in vitro with R1881. In previous experiments, they were quite sensitive to DMSO toxicity. Could you please tell me if R1881 can be dissolved in another solvent, such as ethanol or methanol?

1 answer
1. Technical Support
  
  6 months ago
  
  DMSO is the only solvent that is validated.
  
  Helpful?

Reviews

No rating value